Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win

Amgen (NASDAQ: AMGN) CEO Bob Bradway said in the big biotech's second-quarter conference call last month that Amgen was "looking at ways to grow through business development." We now know one of those ways.